Date
Past
2015
2016
2017
2018
2019
2020

hTERT Immortalized Cells

Unique tools for tissue-relevant research

12/14/2013 — 12/18/2013

ATCC Human telomerase (hTERT) immortalized cell lines combine the in vivo nature of primary cells and the long culture life of continuous cell lines. This section will provide an overview of the hTERT-immortalized cell line collection, and will examine the use of RPTEC/TERT1 (ATCC® No. CRL-4031™) and TIME (ATCC® No. CRL-4025™) cell lines to demonstrate how hTERT-immortalized cell lines can help you reach your research goals.

Abstract: To provide a better research tool for studying Parkinson’s disease, we generated three iPSC lines, from dermal fibroblasts of a donor diagnosed with Parkinson’s disease. To more effectively model Parkinson disease, we have sequenced all exons of the Parkinson’s iPSC lines along with their parent. Importantly, there are three amino acid changes within the LRRK2 gene at positions 50 (R50H), 723 (I723V), and 2397 (M2397T), which have previously been reported in Parkinson’s patients.

4/6/2013 — 4/10/2013

Abstract: Increased understanding of cancer genome is affecting every corner of cancer research. Although human tumor cell lines have been used as essential tools for decades, there are only a few cell line panels have been developed for the drug screening. There is a gap between the new knowledge of cancer genome and the cell line based platforms for both basic and translational research. Here, we show that new generation tumor cell panels are filling the gap. The panels were generated by selecting authenticated cell lines derived from variant cancer types, and annotated with genetic alteration information generated by large scale sequencing projects such as the Catalog of Somatic Mutations in Cancer (COSMIC) and the Cancer Cell Line Encyclopedia (CCLE). To capture the genetic diversity of cancer, each panel includes cell lines with varying gene mutation complexity. To further facilitate targeted drug discovery, the molecular signature tumor cell line panels focus on individual driver genes, critical protein kinases, transcription factors and cell signaling pathways. Those panels have been analyzed to verify gene mutation, gene expression, protein expression and bio-functions.

Development of the PI3K Pathway Inhibitors

How to choose the right cell line

10/1/2012 — 10/3/2012

The phosphatidylinositol 3-kinase (PI3K) cell signal transduction pathway plays a central role in critical cell processes, such as proliferation, apoptosis, metabolism, and angiogenesis. But mutations in several of the enzymes in the PI3K pathway have been implicated in the pathogenesis of several types of cancer. As such, the family of enzymes comprising the PI3K pathway presents an opportunity for potential cancer therapies. Targeted development of PI3K pathway inhibitors is a complicated endeavor, but recent cancer genome research has opened new treatment targets and drug-development paradigms with relevance to PI3K. Tumor cell panels offer a platform for evaluating anticancer agents. ATCC has developed several cell panels with tumor cell lines that feature mutations along the PI3K pathway. Also, ATCC has created gene mutation lists that contain annotations of its tumor cell line collection with data from the Sanger Institute COSMIC database. These research tools inform the use of the cell lines as model systems and for drug development. This module discusses the PI3K pathway mutation cell lines and gene mutations lists.

Abstract: Induced pluripotent stem cells (iPSCs) have the potential to transform biomedical research and drug discovery. However, several hurdles exist for the free dissemination of these research materials, so the cells are difficult to obtain from other laboratories. Therefore, rates of sharing for iPSCs are not what they could be. ATCC is working to create a repository of iPSC materials to enable wider and faster access to iPSCs to support the research community. By professionally managing the roadblocks to reagent distribution as a biorepository, ATCC accelerates research advances by facilitating the sharing and distribution of iPSC. The organization also is establishing a mechanism to protect the commercial interests of stakeholders while still enabling commercial use of these materials. The organization strives to make it easy to contribute cells, as well as easy to access these materials. It has instituted standard processes and quality control procedures for iPSCs, which will improve consistency and reliability when used in research. In addition, the use of materials transfer agreements help define commercial use to avoid potential disputes. ATCC has recently licensed the rights to use technology from the laboratory of Prof. Shinya Yamanaka (Kyoto University) for reprogramming genes to create iPSCs, and is pursuing the rights to distribute cells created by other methods.